VADIS, NCT02636582: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer |
|
|
| Completed | 2 | 43 | US | Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, E75 Plus GM-CSF, E75 Vaccine Plus GM-CSF, HLA A2/A3-Restricted HER-2/neu Peptide Vaccine Plus GM-CSF, Nelipepimut-S Plus Sargramostim, NeuVax Plus GM-CSF, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery | National Cancer Institute (NCI) | Breast Ductal Carcinoma In Situ | 07/19 | 05/23 | | |